The Annual General Meeting of Nobel Biocare Holding AG Approved All Proposals of the Board of Directors


KLOTEN, Switzerland, April 26, 2007 (PRIME NEWSWIRE) -- Nobel Biocare Holding AG's (Other OTC:NBCHF) Annual General Meeting in Zurich, Switzerland, today endorsed all proposals put forward by the Board of Directors.

The Annual General Meeting approved a dividend of CHF 4.25 gross per bearer share of CHF 2.00 nom. on the share capital entitled to dividends = total CHF 112,163,947.

The dividend will be paid on 2 May, 2007, which is also the ex-dividend day.

The following Board members were re-elected: Stig Eriksson, Antoine Firmenich, Robert Lilja, Jane Royston, Domenico Scala, Rolf Soiron and Ernst Zaengerle.

Rolf Watter was elected as a new board member. According to the by-laws, all Board members have been elected for a one-year term.

At the first board meeting following the Annual General Meeting, Rolf Soiron has been re-elected as Chairman of the Board.

KPMG, Zurich, has been re-elected for a one-year term of office as auditor and group auditor.

A biography of new board member Rolf Watter is available at http://www.newsbox.ch/public/11111/att/12001_cvrolfwatterpdf.pdf

Nobel Biocare is a medical devices group and the world leader in innovative esthetic dental solutions with its brands Branemark System(r), NobelReplace(tm), NobelSpeedy(tm), NobelPerfect(r), NobelDirect(r), Replace Select, (dental implants), Procera(r) (individualized dental prosthetics), NobelGuide(tm) (complete patient rehabilitation program) and NobelSmile(tm) (patient education campaign). Nobel Biocare is a one-stop shop for restorative esthetic dentistry, offering a wide range of innovative Crown and Bridge and Implant products, as well as training and education, patient information and clinically documented treatment concepts. Nobel Biocare has over 2,100 employees and recorded revenue of EUR 601 million in 2006. The Company is domiciled in Zurich, Switzerland with headquarters in Zurich and in Gothenburg, Sweden. Production takes place at four production sites located in Sweden and the USA. Nobel Biocare has direct sales organizations in 34 countries. The shares of the parent company Nobel Biocare Holding AG are listed on the SWX Swiss Exchange and on the Stockholm Stock Exchange, Sweden.

www.nobelbiocare.com

www.nobelsmile.com


            

Contact Data